Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Inclusion Criteria

• Are 18 years of age or older
• Have histologic evidence of locally or regionally advanced or stage IV malignancy
• Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)
• Have an understanding of the protocol and its requirements, risks, and discomforts
• Are willing to undergo peripheral blood collection at the time points mentioned in the protocol
• Are able and willing to sign an informed consent

Exclusion Criteria

• Inability on the part of the patient to understand the informed consent or be compliant with the protocol
• Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)
• Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception